omniture
logo
Search
普方生物制药（苏州）有限公司
Media Room

Latest News

rss

ProfoundBio to Participate in the Bank of America 2023 Healthcare Trailblazers Private Company Conference

SEATTLE, Oct. 5, 2023 /PRNewswire/ -- ProfoundBio, a clinical-stage biotechnology company focused o...

2023-10-05 20:00 2402

ProfoundBio Announces Upcoming Scientific Presentations at SITC 2023

SEATTLE, Sept. 28, 2023 /PRNewswire/ -- ProfoundBio, a clinical-stage biotechnology company focused...

2023-09-28 20:00 2217

ProfoundBio to Participate in the 21st Annual Morgan Stanley Conference

SEATTLE, Aug. 28, 2023 /PRNewswire/ -- ProfoundBio, a clinical-stage biotechnology company focused ...

2023-08-28 20:00 1255

ProfoundBio Announces Further Advancement of Lead Programs - PRO1184 (Rinatabart Sesutecan) and PRO1160 in the Clinic

* PRO1160 first patient dosed in the US * China NMPA clearance for PRO1184 (rinatabart sesutecan...

2023-05-26 20:00 2336

ProfoundBio Highlights Broad Antitumor Activity in Preclinical Models and Trial-in-Progress for PRO1184 at AACR 2023 Annual Meeting

WOODINVILLE, Wash. and SUZHOU, China, March 24, 2023 /PRNewswire/ -- ProfoundBio, a clinical stage ...

2023-03-24 20:00 3225

ProfoundBio Announces Initiation of First-in-Human Trial for PRO1184, a Folate Receptor Alpha-Directed ADC with a Topoisomerase 1 Inhibitor Payload, and Receives FDA "Study May Proceed" Letter for PRO1160, a CD70-Directed ADC

* PRO1184 first-in human study initiated and first patients dosed * PRO1160 first-in-human study...

2023-01-03 20:00 2503

ProfoundBio Receives FDA "Study May Proceed" Letter for PRO1184, a Folate Receptor Alpha-Directed ADC with a Topoisomerase 1 Inhibitor Payload, and Welcomes Naomi Hunder, M.D., as Chief Medical Officer

SUZHOU, China and WOODINVILLE, Wash., Aug. 3, 2022 /PRNewswire/ -- ProfoundBio, an oncology biother...

2022-08-03 20:00 1859

ProfoundBio Announces Completion of $70 Million Series A+ Financing to Advance Antibody-Drug Conjugate (ADC) Programs into the Clinic

- Advance PRO1184 and PRO1160 into clinical trials - Accelerate multiple programs into preclinical d...

2022-06-02 20:00 2580

ProfoundBio to Highlight Programs and Technology at AACR 2022 Annual Meeting; Welcomes Zhu Chen, PhD, as Chief Scientific Officer

SEATTLE, Wash. and SUZHOU, China, March 8, 2022 /PRNewswire/ -- ProfoundBio announced that preclini...

2022-03-09 06:58 4514

ProfoundBio Announces Presentation on Novel, Proprietary Linker-Drug Technology to Enable Antibody-Drug Conjugates (ADCs) with an Expanded Therapeutic Window at the AACR-NCI-EORTC International Conference

WOODINVILLE, Wash. and SUZHOU, China, Oct. 7, 2021 /PRNewswire/ -- ProfoundBio announces that precl...

2021-10-08 11:39 2020

ProfoundBio Announces Completion of More Than $55 million Series A Financing to Advance Novel Antibody-Drug Conjugate (ADC) Portfolio

WOODINVILLE, Wash. and SUZHOU, China, July 12, 2021 /PRNewswire/ -- ProfoundBio announced the closi...

2021-07-12 17:00 2402